SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility and intense social media debate after President Trump publicly endorsed the company, an move that community members are interpreting as both a strategic signal of long-term government backing and an attempt to counter recent aggressive short-selling campaigns led by figures like Michael Burry. While bulls view the endorsement and embedded defense contracts as a long-term catalyst, skeptics are actively questioning the ethics of the executive intervention and debating the competitive threat posed by emerging AI rivals.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as investors digest a stronger-than-expected operational update, featuring a significant cash position and a clear ramp-up in production for optical engines targeting AI data centers. The community is actively discussing the companys strategic integration with major industry players like Marvell and the potential for a gamma squeeze as short interest meets limited share availability.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether the stock is a deep-value opportunity or a long-term play against concerns of AI-driven obsolescence. Community members are actively discussing potential short squeezes, management's buyback strategies, and the competitive impact of Anthropic, with many bullish investors holding for the long term despite current volatility.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is experiencing significant downward pressure as market sentiment shifts due to concerns over AI integration and increased competition from emerging AI models. While bulls highlight strong fundamental growth and ServiceNow's partnership with Anthropic as long-term tailwinds, the community is currently debating whether this recent price action represents a generational buying opportunity or a structural shift in the software-as-a-service (SaaS) business model.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense volatility and heavy volume as traders react to a new multi-million dollar order for its 800G data center transceivers, fueling intense debates between momentum-driven bulls and short-sellers citing valuation concerns. The community is actively tracking the stock's role in the broader AI infrastructure buildout while debating whether this latest contract signals sustainable growth or a temporary rally in an overextended sector.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing massive social media engagement and high-volume price action driven by investor excitement over its "Nvidia-adjacent" foundry partnerships and the potential for its proprietary EO polymer technology to become a standard in high-speed AI data infrastructure. Community sentiment remains polarized, with bulls tracking upcoming industry conferences and technical integration milestones, while bears point to the company's long-term history of pre-revenue status and recurring dilution concerns.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is capturing significant investor attention as shares experience high volatility ahead of a pivotal corporate update regarding the DENALI clinical trial. The community remains heavily divided, with some investors betting on a potential buyout or institutional accumulation due to the company's substantial cash position, while others express concerns over clinical trial risks and recent insider movements.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as investors react to the cross-listing of new ETPs in Europe and persistent community speculation regarding potential integration with X and upcoming space missions. Traders are actively debating the asset's long-term utility versus its status as a meme coin, while monitoring technical price levels amidst broader market volatility.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is currently experiencing intense volatility following strong quarterly earnings, with a fierce debate unfolding between investors betting on AI-driven revenue acceleration and skeptics concerned about high valuations and competitive threats from emerging AI models. The community is actively discussing the stock's sharp price swings and divided perspectives on its long-term viability in an evolving SaaS landscape, with many traders keeping a close watch on key support levels as they navigate the broader market's uncertainty.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently trending as a primary proxy play for SpaceX, driven by intense investor anticipation surrounding a potential future IPO and the company's strategic accumulation of SpaceX equity through spectrum deals. Community sentiment remains polarized between bullish traders targeting a breakout based on SpaceX's massive valuation and skeptics highlighting the company's significant debt load and ongoing operational challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharmaceutical Stocks To Follow Today - April 10th

Eli Lilly and Company, Abbott Laboratories, Pfizer, AbbVie, Novo Nordisk A/S, Organon & Co., and Zentalis Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.read more...

<ul class="summary-bullets"><li>Zentalis selected the 400 mg dose of its drug to treat ovarian cancer after it showed a higher response rate than the 300 mg dose.</li><li>The company expects to complete enrollment and report topline results from the trial by the end of 2026.</li><li>This comes just two weeks after the FDA approved Cort’s ovarian cancer treatment months ahead of schedule.</li></ul>Shares of Zentalis Pharmaceuticals (ZNTL) soared over 40% on Friday to their highest level since June 2024, after a bullish analyst call highlighted improved efficacy from a higher dose of its ovarian cancer drug while maintaining a comparable safety profile.Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating, according to The Fly. This implies a potential 56% upside from the stock’s current price. The firm cited the price target change to the increased confidence in the drug’s chances of success in platinum-resistant ovarian cancer.<h2 class="st-heading-2">Zentalis Picks 400 MG Dose For Future Trials</h2>On Thursday, Zentalis announced encouraging interim results from its DENALI Part 2a study of Azenosertib, an oral therapy, in platinum-resistant ovarian cancer, supporting the drug’s further late-stage development.The biotech firm selected the 400 mg once-daily dose (five days on, two days off) after it showed a clearly higher response rate than the 300 mg dose, while maintaining a similar safety profile. The 400 mg dose will now be used in the ongoing Phase 2 DENALI trial and the Phase 3 ASPENOVA study.Zentalis expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026.<h2 class="st-heading-2">FDA Approved Corcept’s Ovarian Cancer Drug Months Ahead Of PDUFA Date</h2>The results are crucial, as they allow Zentalis to move towards potential regulatory approval. Just two weeks earlier, the U.S. Food and Drug Administration (FDA) <a href="https://stocktwits.com/news-articles/markets/equity/cort-stock-skyrockets-35-after-early-fda-nod-for-ovarian-cancer-drug/cZ3YMziRISr">approved</a> Corcept Therapeutics’ (CORT) ovarian cancer treatment.The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received treatment.Notably, the FDA’s decision came way ahead of schedule, as the therapy had been assigned a Prescription Drug User Fee Act (PDUFA) target date of July 11, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ZNTL">ZNTL</a> on Stocktwits changed to ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the company’s valuation to explode seven to 10-fold if the drug is successful in monotherapy.<stembedurl>https://stocktwits.com/Lukey63/message/649876699</stembedurl>However, another user said the stock is overvalued, highlighting the company’s pipeline.<stembedurl>https://stocktwits.com/ScorpionScarlet/message/649934768</stembedurl>Year-to-date, the stock has shot up more than 370%.&nbsp;

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally

Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating after the company posted the interim results for its ovarian cancer drug.

ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update

Equity

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00

Guggenheim lifted their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research note on Friday...

These Stocks are Heating Up Fast

Top stocks to trade this afternoon. $ONCO, $KBLB, $ARAI, $EOSE, $ZNTL

Brokers Issue Forecasts for ZNTL FY2030 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Zentalis Pharmaceuticals in a report released on...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen cut Zentalis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim

Guggenheim reaffirmed a "buy" rating and issued a $6.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus rating of "Hold" from the six ratings firms that are covering the stock, MarketBeat reports. One research...

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

Investors are rallying around positive pivotal trial data for azenosertib in ovarian cancer, fueling long-term price targets.

Traders are cautious about the possibility of share dilution and secondary offerings given the company's lack of current revenue.

Momentum traders are eyeing key technical resistance levels at $6.50 and $7.00 to validate a continued bull run.

The stock is attracting attention after receiving price target upgrades from analysts, with some forecasting a move toward $10.

Current Price	$6.52
Prev Close	$4.42
Open	$4.56
Dividend Yield	0.00%
50-Day Moving Average	$2.55
Beta	1.73
Avg. Volume	631,365.14
PE Ratio	-2.32

52-Week High	$4.50
52-Week Low	$1.09
Market Capitalization	$313.52M
EPS (Annual)	-$1.91
Price to Book	1.41
Revenue Per Employee	$0.00

ZNTL
Zentalis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZNTL News

ZNTLZentalis Pharmaceuticals Inc